ChemGenex Pharmaceuticals Limited (CXS.AX) Licenses Targeted Platinum IV Compound From The University of Texas M. D. Anderson Cancer Center
10/19/2005 5:12:40 PM
MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--Feb. 9, 2005--
ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today that it has licensed a novel platinum (IV) agent from The University of Texas M. D. Anderson Cancer Center in Houston, Texas, one of the world's most respected cancer research and treatment institutions. The patented molecule, now called CXS299, is a platinum (IV) anti-cancer agent invented by Zahid H. Siddik, Ph.D. and Abdul R. Khokhar, Ph.D., professors in the Department of Experimental Therapeutics at M. D. Anderson Cancer Center. CXS299 is active against cancer cells resistant to approved platinum-based therapies and possesses unique properties that may allow physicians to target patients who are most likely to benefit from therapy.
comments powered by